411 related articles for article (PubMed ID: 34088357)
1. Cellular dormancy in minimal residual disease following targeted therapy.
Ruth JR; Pant DK; Pan TC; Seidel HE; Baksh SC; Keister BA; Singh R; Sterner CJ; Bakewell SJ; Moody SE; Belka GK; Chodosh LA
Breast Cancer Res; 2021 Jun; 23(1):63. PubMed ID: 34088357
[TBL] [Abstract][Full Text] [Related]
2. Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy.
Abravanel DL; Belka GK; Pan TC; Pant DK; Collins MA; Sterner CJ; Chodosh LA
J Clin Invest; 2015 Jun; 125(6):2484-96. PubMed ID: 25961456
[TBL] [Abstract][Full Text] [Related]
3. Tumor dormancy and cancer stem cells: two sides of the same coin?
Kleffel S; Schatton T
Adv Exp Med Biol; 2013; 734():145-79. PubMed ID: 23143979
[TBL] [Abstract][Full Text] [Related]
4. Exploiting Mouse Models to Recapitulate Clinical Tumor Dormancy and Recurrence in Breast Cancer.
Gu Y; Bui T; Muller WJ
Endocrinology; 2022 Jun; 163(6):. PubMed ID: 35560214
[TBL] [Abstract][Full Text] [Related]
5. A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype.
Cheng Q; Chang JT; Gwin WR; Zhu J; Ambs S; Geradts J; Lyerly HK
Breast Cancer Res; 2014 Jul; 16(4):407. PubMed ID: 25060555
[TBL] [Abstract][Full Text] [Related]
6. Impact of obesity on breast cancer recurrence and minimal residual disease.
Ecker BL; Lee JY; Sterner CJ; Solomon AC; Pant DK; Shen F; Peraza J; Vaught L; Mahendra S; Belka GK; Pan TC; Schmitz KH; Chodosh LA
Breast Cancer Res; 2019 Mar; 21(1):41. PubMed ID: 30867005
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease in cancer therapy--Small things make all the difference.
Blatter S; Rottenberg S
Drug Resist Updat; 2015; 21-22():1-10. PubMed ID: 26307504
[TBL] [Abstract][Full Text] [Related]
8. Tumor dormancy: long-term survival in a hostile environment.
Quesnel B
Adv Exp Med Biol; 2013; 734():181-200. PubMed ID: 23143980
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor recurrence in FGFR1-driven breast cancer.
Holdman XB; Welte T; Rajapakshe K; Pond A; Coarfa C; Mo Q; Huang S; Hilsenbeck SG; Edwards DP; Zhang X; Rosen JM
Breast Cancer Res; 2015 Nov; 17():141. PubMed ID: 26581390
[TBL] [Abstract][Full Text] [Related]
10. Cancer Cell Dormancy in Metastasis.
Summers MA; McDonald MM; Croucher PI
Cold Spring Harb Perspect Med; 2020 Apr; 10(4):. PubMed ID: 31548220
[TBL] [Abstract][Full Text] [Related]
11. Tumor dormancy and cancer stem cells: implications for the biology and treatment of breast cancer metastasis.
Allan AL; Vantyghem SA; Tuck AB; Chambers AF
Breast Dis; 2006-2007; 26():87-98. PubMed ID: 17473368
[TBL] [Abstract][Full Text] [Related]
12. Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).
Martin-Castillo B; Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Moreno JM; Corominas-Faja B; Urruticoechea A; Martín ÁG; López-Bonet E; Menendez JA
Cell Cycle; 2013 Jan; 12(2):225-45. PubMed ID: 23255137
[TBL] [Abstract][Full Text] [Related]
13. Local and distant tumor dormancy during early stage breast cancer are associated with the predominance of infiltrating T effector subsets.
Aqbi HF; Coleman C; Zarei M; Manjili SH; Graham L; Koblinski J; Guo C; Xie Y; Guruli G; Bear HD; Idowu MO; Habibi M; Wang XY; Manjili MH
Breast Cancer Res; 2020 Oct; 22(1):116. PubMed ID: 33115528
[TBL] [Abstract][Full Text] [Related]
14. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells.
Lawson DA; Bhakta NR; Kessenbrock K; Prummel KD; Yu Y; Takai K; Zhou A; Eyob H; Balakrishnan S; Wang CY; Yaswen P; Goga A; Werb Z
Nature; 2015 Oct; 526(7571):131-5. PubMed ID: 26416748
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Wnt1 expression reduces the enrichment of cancer stem cells in a mouse model of breast cancer.
Choi AR; Park JR; Kim RJ; Kim SR; Cho SD; Jung JY; Nam JS
Biochem Biophys Res Commun; 2012 Aug; 425(2):436-42. PubMed ID: 22846569
[TBL] [Abstract][Full Text] [Related]
16. Tumor dormancy as an alternative step in the development of chemoresistance and metastasis - clinical implications.
Rossari F; Zucchinetti C; Buda G; Orciuolo E
Cell Oncol (Dordr); 2020 Apr; 43(2):155-176. PubMed ID: 31392521
[TBL] [Abstract][Full Text] [Related]
17. The acidic microenvironment as a possible niche of dormant tumor cells.
Peppicelli S; Andreucci E; Ruzzolini J; Laurenzana A; Margheri F; Fibbi G; Del Rosso M; Bianchini F; Calorini L
Cell Mol Life Sci; 2017 Aug; 74(15):2761-2771. PubMed ID: 28331999
[TBL] [Abstract][Full Text] [Related]
18. Conditional mouse models demonstrate oncogene-dependent differences in tumor maintenance and recurrence.
Tilli MT; Furth PA
Breast Cancer Res; 2003; 5(4):202-5. PubMed ID: 12817992
[TBL] [Abstract][Full Text] [Related]
19. Metastatic Cell Dormancy and Re-activation: An Overview on Series of Molecular Events Critical for Cancer Relapse.
Muzes G; Sipos F
Anticancer Agents Med Chem; 2017; 17(4):472-482. PubMed ID: 27592547
[TBL] [Abstract][Full Text] [Related]
20. The Relationship Between Dormant Cancer Cells and Their Microenvironment.
Linde N; Fluegen G; Aguirre-Ghiso JA
Adv Cancer Res; 2016; 132():45-71. PubMed ID: 27613129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
